Skin Disease in Transplant Recipients and Immunosuppressed Patients

The session titled "Skin Disease in Transplant Recipients and Immunosuppressed Patients" discussed the significant skin cancer risks associated with organ transplantation and immunosuppression. The speaker, Dr. Sean Christensen, introduced the topic by highlighting advancements in organ transplantation, including the development of immunosuppressive medications that enabled increased transplant success rates since the 1950s. He noted that while organ transplants enhance life post-surgery, they drastically increase skin cancer risk, with a notably high burden among these patients—about 50% will develop skin cancer, specifically squamous cell carcinomas (SCC). The session emphasized various immunosuppressive medications, their respective cancer risks, such as azathioprine, which is linked to a significant increase in skin cancer rates. The discussion continued on types of immunosuppression beyond transplantation, including risks associated with conditions like HIV and hematologic malignancies. Additionally, the rising concern regarding infections in immunosuppressed patients was addressed, noting that infections are a leading cause of death in this group. The importance of multidisciplinary care collaboration was underlined, indicating that coordinated follow-up and management could reduce morbidity from skin cancers. The session concluded by emphasizing ongoing research and the need for awareness in dermatology practices concerning the specialized care required for this patient population.